Pharma M&A deal value up 31% YoY in 2025YTD amid return of mega-deals
Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.
